ProShare Advisors’s Eterna Therapeutics ERNA Stock Holding History

ProShare Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$22K	–	1900
2022 Q1	$22K	Sell	1 -1	-50%	-$19K	﹤0.01%	2171
2021 Q4	$58K	Buy	+2	New	+$109K	﹤0.01%	2266

Other funds holding ERNA

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ProShare Advisors's ERNA Position: Q2 2022 in Review

ProShare Advisors sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 1 share — an estimated $22K sold.

ProShare Advisors first reported a position in ERNA in Q4 2021 and held it in 2 quarters. The position peaked at $58K in Q4 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

ProShare Advisors reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 1 Eterna Therapeutics share in Q2 2022, an estimated $22K.
ProShare Advisors first reported a position in Eterna Therapeutics in Q4 2021 and held it in 2 quarters.
ProShare Advisors's Eterna Therapeutics position peaked at $58K in Q4 2021.
34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.